Nuveen Asset Management, LLC Bei Gene, Ltd. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 405,209 shares of BGNE stock, worth $91.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

405,209

Previous 162,649 149.13%

Holding current value

$91.9 Million

Previous $36.5 Million 104.97%

% of portfolio

0.02%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$174.72 - $246.04 $42.4 Million - $59.7 Million	242,560 Added 149.13%	405,209 $74.8 Million
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $23.4 Million - $36.5 Million	162,649 New	162,649 $36.5 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $1.8 Million - $2.25 Million	10,000 Added 18.8%	63,200 $11.4 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $5.88 Million - $8.8 Million	33,000 Added 163.37%	53,200 $9.49 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $474,166 - $603,900	2,200 Added 12.22%	20,200 $4.35 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $10.5 Million - $19.2 Million	-83,516 Reduced 82.27%	18,000 $3.96 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $627,104 - $962,257	4,758 Added 4.92%	101,516 $13.7 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $121,110 - $216,050	1,000 Added 1.04%	96,758 $15.7 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $3.79 Million - $6.98 Million	25,900 Added 37.08%	95,758 $18.1 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $1.66 Million - $2.6 Million	6,666 Added 10.55%	69,858 $18.9 Million
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $758,284 - $1.22 Million	3,038 Added 5.05%	63,192 $22.9 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $1.6 Million - $2 Million	5,462 Added 9.99%	60,154 $20.6 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $831,441 - $1.22 Million	3,190 Added 6.19%	54,692 $19 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $1.61 Million - $2.31 Million	-7,287 Reduced 12.4%	51,502 $13.3 Million
Q3 2020 Nov 16, 2020	SELL	$189.18 - $286.44 $2.97 Million - $4.5 Million	-15,694 Reduced 21.07%	58,789 $16.8 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $3.17 Million - $5 Million	25,583 Added 52.32%	74,483 $14 Million
Q1 2020 May 14, 2020	SELL	$121.84 - $173.19 $840,696 - $1.2 Million	-6,900 Reduced 12.37%	48,900 $6.02 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $1.24 Million - $2.24 Million	-10,745 Reduced 16.15%	55,800 $9.25 Million
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $590,989 - $726,621	-4,900 Reduced 6.86%	66,545 $8.15 Million
Q2 2019 Aug 15, 2019	BUY	$113.99 - $146.86 $8.14 Million - $10.5 Million	71,445 New	71,445 $8.86 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

42.4M

Call Options Held

135K

Put Options Held

111K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Bei Gene, Ltd. Transaction History